Halozyme Therapeutics Inc. Live Stock Price Today, Share Analysis and Chart

Name: Halozyme Therapeutics Inc.: Is Infosys Ltd. worth buying?
Item: Halozyme Therapeutics Inc.
Rating: 3.2093195
Author: Trendlyne DVM scores

Mid-range Performer

about

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary ...

76.33 -0.57 (-0.74%)

New 52W High in past week

1.3M

XNAS Volume

XNAS 15 Sep, 2025 5:30 PM (EDT)

High Financial Strength

77.8 / 100

Mid Valuation

42.0 / 100

Technically Neutral

59.2 / 100

Mid-range Performer These stocks are with strong quality. Their reasonable financials and technical aspects successfully gather investor's interest. View Similar Embed DVM

1Yr Price target downside is -8%

9 analysts

Halozyme Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Halozyme Therapeutics Inc. Live Stock Price Today, Share Analysis and Chart

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary ...

New 52W High in past week

SWOT Analysis

Halozyme Therapeutics Inc Live Price Chart